

EXHIBIT A

MARIO A. GONZÁLEZ, Ph.D.

Professional Title: President & CEO, GloboMax Américas, specializing in product development and pharmacokinetics research & a GloboMax Service Group company

Business Address: GloboMax Américas LLC
17140 Arvida Parkway, Suite 3
Weston, FL 33326

Telephone: (954) 349-9995
Fax: (954) 349-9093
Email: GonzalezM@GloboMaxAmericas.com

Education: B.S. Pharmacy with Honors,
University of Texas, Austin, 1964
M.S. Pharmacy,
University of Texas, Austin, 1967
Ph.D. Pharmacokinetics,
University of California, San Francisco, 1975

Positions Held: Pharmacist-Tovar Pharmacy
Austin, Texas, 1965-1966
Pharmacist-Garcia Pharmacy
Alice, Texas, 1966-1967
Trainee on NIH Training Grant
University of California, San Francisco, 1968-1974
Assistant Professor of Biopharmaceutics
School of Pharmacy
University of Colorado, Boulder, 1974-1977
Affiliate Assistant Professor of Pharmacology
School of Veterinary Medicine
Colorado State University, Fort Collins, 1976-1977
Summer Visiting Professor, Abbott Laboratories
N. Chicago, Illinois, 5/77-8/77
Assistant Professor of Pharmaceutics
School of Pharmacy and Pharmacal Sciences
Purdue University
West Lafayette, Indiana 1977-1980
Manager, Clinical Pharmacology
Key Pharmaceuticals, Inc.
Miami, Florida, 1980-1983
Director, Biopharmaceutics and Pharmacokinetics
Key Pharmaceuticals, Inc.
Miami, Florida, 1983-1986
Director, Biopharmaceutics and Pharmacokinetics
Schering-Plough Research,
Miami, Florida, 7/86-4/91
President, P'Kinetics, Inc.
Pembroke Pines, Florida, 4/91-11/99
President, GloboMax Américas LLC
Pembroke Pines, Florida, 11/99-present

Membership in Scientific and Professional Societies:

American Association of Pharmaceutical Scientists
American Association of Colleges of Pharmacy
Controlled Release Society
Rho Chi
Sigma Xi

Symposia and Invited Lectures:

1. Lecturer at 10th Annual Meeting of the American Society of Consultant Pharmacists in Dallas. Topic: Pharmacokinetic Considerations in Geriatrics, November, 1979.
2. Controlled-Release Delivery Systems for Theophylline: lecture at Industrial Pharmaceutical R & D Symposium, Oral Controlled Drug Administrations, Rutgers University, January, 1983.
3. Speaker at International Industrial Pharmacy Meeting (Lakeway Meeting), Topic: "Sustained-Release Theophylline Formulations" Austin, Texas, February, 1983.
4. Invited lecture entitled Pharmacokinetics and Its Utilization in a Pharmaceutical Dosage Regimen. Presented at the Miami Meeting of the Engineering in Medicine and Biology Society, June, 1983.
5. Speaker at 9th Annual Spring Meeting of AOAC (Association of Official Analytical Chemists). Topic: Problem Solving in Dosage from Design Using *In Vitro-In Vivo* Correlation, Philadelphia, April, 1984.
6. The Use of Pharmacokinetics in the Evaluation of Controlled-Release Delivery Systems: lecture at 12th International Symposium on Controlled Release of Bioactive Materials, Geneva, Switzerland, July, 1985.
7. Use of *In Vitro-In Vivo* Correlations in Dosage Form Design of Sustained-Release Theophylline: lecture at Symposium during Congress of the European Society of Pneumology, Milan, Italy, September, 1985.
8. Lecturer at Arden House Conference on Industrial Pharmacy. Topic of three-hour lecture: Evaluation of Oral Controlled-Release Dosage Forms, January, 1986.
9. Coordinator of Educational Session at National AphA Meeting in Atlanta, Title of Symposium: Transdermal Drug Delivery: Problems and Perspectives, March, 1988.
10. Seminar entitled Biopharmaceutic/Pharmacokinetic Considerations for Controlled-Release Dosage Forms. Presented at Nortec Oral Controlled-Release Dosage Forms Symposium, March, 1988.

11. Lecture entitled **Controversies in the Interpretation of Transdermal Nitroglycerin Pharmacokinetics**, presented at the **Symposium on Transdermal Nitroglycerin Therapy in Ischemic Heart Disease**, Newport Beach, June, 1988.
12. **PDD Symposium Chairman-Physicochemical Means of Improving Skin Permeation**, AAPS, Orlando Meeting, November, 1988.
13. Panel member at **AAPS/FDA Workshop on *In Vitro* and *In Vivo* Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms**. Presentation entitled **Bioequivalence Considerations: Fluid Content and Timing of Meals**, Washington, D.C., December, 1988.
14. Lecture on **Pharmacokinetic Evaluation of Transdermal Drug Delivery**, Seminar at Bureau of Drug Research, Health Protection Branch, Ottawa, Ontario, March, 1989.
15. Seminar entitled **Biopharmaceutic/Pharmacokinetic Considerations for Controlled-Release Dosage Forms**. Presented at **Nortec Oral Controlled-Release Dosage Forms Symposium**, April, 1989.
16. Panel member at **Bio International '89: Session title: Food Effects in Bioequivalency Evaluations**, Toronto, Ontario, October, 1989.
17. **PPDM Symposium Chairman: Trials and Tribulations with Pharmacokinetic Studies**, AAPS, Atlanta Meeting, October, 1989.
18. **Co-Chairman of Transdermal Focus Podium**, AAPS, Las Vegas Meeting, November, 1990.
19. **Speaker at 20th International Conference on Chronobiology; Satellite Conference on Chronopharmacology and Chronotherapy**. Topic: **Chronopharmacology of Theophylline**, Jerusalem, Israel, June, 1991.
20. **Update Lecturer, Pharmacy World Congress**. Topic: **Trends in Transdermal Drug Delivery**, Washington, D.C., September, 1991.
21. **PDD/PPDM Symposium Chairman: Pharmacokinetics and Pharmacodynamics of Transdermal Delivery Systems**, AAPS, Washington, D.C. Meeting, November, 1991.
22. **Speaker at "Nitrates for the Nineties"**. Topic: **Pharmacokinetics of Transdermal Nitroglycerin**, Gleneagles, Scotland, December, 1991.
23. **Speaker at International Conference on Oral Controlled-Release Dosage Forms**. Topic: **Bioevaluation of Oral Sustained-Release Dosage Forms**. Berlin, Germany, April, 1992.
24. **Speaker at AAPS/FDA/USP Workshop on the Scale-Up of Oral Solid Extended Release Formulations**. Topic: ***In Vivo/In Vitro* Correlations: Mathematical Approach**, Arlington, VA, September, 1992.
25. **Speaker at Congreso Internacional Quimico Farmaceutico**, Santiago, Chile, August, 1992.

Topics:

**Transdermal Drug Delivery Systems. Design and Evaluation
Pharmacokinetic Evaluation of Transdermal Drug Delivery
Trends in Transdermal Drug Delivery**

26. **Speaker at 32nd Annual Eastern Pharmaceutical Technology Meeting (EPTM). Topic: Design of Controlled Release Formulations Through *In Vitro/In Vivo* Correlations. Princeton, New Jersey, October, 1992.**
27. **Co-Chair Drug/Polymer Interactions in Pharmaceutical Formulations, AIChE Annual Meeting, November, 1992.**
28. **Speaker at Technomic Conference: Oral Controlled-Release Dosage Forms- Research and Development, Evaluation, Scale-Up, Manufacture, Approval and Marketing. Topic: Bioevaluation of Oral Controlled-Release Formulations. Zurich, Switzerland, June, 1993.**
29. **Research seminars presented at Schools of Pharmacy:**
 - a) **University of California, San Francisco - 1979**
 - b) **University of Illinois Medical Center - 1979**
 - c) **University of Tennessee - 1982 and 1989**
 - d) **University of Geneva, Switzerland - 1984**
 - e) **University of West Virginia - 1985**
 - f) **University of Michigan - 1986 and 1990**
 - g) **Hebrew University, Jerusalem, Israel - 1991**
 - h) **University of Geneva, Switzerland - 1993**
 - i) **Nova Southeastern University, Miami - 1995**
30. **Lecturer at the International Course on Modern Pharmaceutical Dosage Forms, Pontificia Universidad Catolica de Chile, Santiago, Chile, November 30-December 3, 1993.**
31. **Speaker at FDA seminar on "Bioevaluation of Oral Controlled-Release Formulations and *In Vitro/In Vivo* Correlations ", Rockville, MD, December 7, 1993.**
32. **Speaker at TGA (Australian Therapeutic Goods Administration) Continuing Education Seminar on "Clinical Pharmacokinetics of Transdermal Nitroglycerin", Canberra, Australia, March 30, 1994.**
33. **21st International Symposium on Controlled Release of Bioactive Materials: Chair & Speaker at Workshop on Scale-up & Manufacturing Site Change, topic "*In Vitro/In Vivo* Correlations", Nice, France, June 24-25, 1994.**
34. **Moderator and co-author of Consensus Report for the AAPS/FDA Workshop on Evaluation of Orally Administered Highly Variable Drugs and Drug Formulations, Arlington, VA, March 6-8, 1995.**

35. Panel member at FIP BIO International '96: Session title: BA/BE of Extended and Controlled Release Products, Toyko, April 23, 1996.
36. Speaker & Co-Chair at AAPS/FDA/USP Workshop on Scale-Up of Adhesive Transdermal Drug Delivery Systems. Topics: Compositional Variables-Case Study 1: Adhesive Polymer Sources and Consensus Report: BE Studies vs *In Vitro*, Arlington, VA, April 29-May 1, 1996.
37. Speaker at the American College of Osteopathic Family Physicians Annual Meeting on "A Pharmacokinetic Review of Second Generation Antihistamines", Nashville, TN, April 3, 1998.
38. Speaker at the American Academy of Physician Assistants Annual Meeting on "Antihistamines: Pharmacokinetic Considerations in Their Selection", Salt Lake City, Utah, May 24, 1998.
39. Speaker at Respiratory 2000 on " Pharmacokinetics of Second-Generation Antihistamines", New York, NY, October 22, 1998.
40. Speaker at the American College of Allergy, Asthma & Immunology Annual Meeting on "Pharmacokinetic Considerations in Selecting an Antihistamine", Philadelphia, PA,
41. November 7, 1998.
42. Presented 1 day Workshop on "The Role of Pharmacokinetics in the Evaluation of Controlled-Release Formulations" at the Controlled Release Society/Argentine Chapter, 3rd International Symposium, Buenos Aires, Argentina, August 9, 1999
43. Speaker on "Transdermal Delivery Systems-BE and Analytical Concerns", at the 32nd annual Congreso Nacional de Ciencias Farmacéuticas: AAPS Symposium, Puerto Vallarta, Mexico, October 26, 1999.
44. Moderator of Symposium titled" New Approaches to BE: The Biopharmaceutics Classification System" at the Pan American Health Organization Conference: Trends in Regulatory Standards on Active Materials and Bioequivalence, Washington D.C., November 5, 1999.
45. Speaker at the VI Congreso de las Federación Farmacéutica Sudamericana (FEFAS): "*In Vitro/In Vivo* Correlation in the Evaluation of Extended-Release Dosage Forms", Montevideo, Uruguay, April 27, 2000.
46. Speaker at the Congreso Farmacéutico Argentino: "Transdermal Products - The Present & The Future", Buenos Aires, Argentina, April 29, 2000.
47. Co-Chair of CRS Workshop: *In Vitro/In Vivo* Correlations Applicable to Extended-Release Formulations, Paris, France, July 8-9, 2000.
48. Speaker at CRS Workshop: "Wagner-Nelson Analysis for *In Vitro/In Vivo* Correlations", Paris, France, July 8, 2000.

49. Speaker at Bioequivalence Evaluation of Oral Extended-Release Formulations Workshop: "Bioequivalence Requirements" & Scale-up & Post-Approval Changes (SUPAC) Biowavers", São Paulo, Brazil, August 10, 2000.
50. Speaker at X Congreso Nacional de Ciencias Farmacéuticas: "Correlaciones *In Vitro/In Vivo*," Panama City, Panama; September 2, 2000.
51. Speaker at CRS Workshop: "Correlaciones *In Vitro/In Vivo*", Vitoria-Gasteiz, Spain; September 20, 2000.
52. Speaker at the XXXIV Congreso Nacional de Ciencias Farmacéuticas: "Requisitos Para Bioequivalencia," Ixtapa, México, October 23, 2000.
53. Speaker at the XVII Panamerican Congress of Pharmacy and the V World Congress of Pharmacists of Portuguese Language: "Biodisponibility and Bioequivalencia," Rio de Janeiro, Brazil; November 3, 2000.
54. Poster Presentation at the Congreso de Ciencias Farmacéuticas de las Américas (PCA): "*In Vitro/In Vivo* Correlation with a Liquid Extended-Release H₁ Antihistamine Formulation", Orlando, Florida; March 29, 2001.
55. Speaker at the College of Chemistry, Universidad Nacional Autónoma de México, (UNAM): "Correlaciones *In Vitro/In Vivo*," May 29, 2001.
56. Moderator & Organizing Committee Chair for Asociación Farmacéutica Mexicana's (AFM) Seminario de Farmacología Clínica, Mexico City, Mexico; May 31-June 1, 2001.
57. Speaker at the III Congreso Regional de Químico Farmacéutico Biólogos: "El Uso de *In Vitro/In Vivo* en el Desarrollo de Medicamentos", Monterrey, Mexico; August 31, 2001.
58. Workshop Speaker at the V Congreso del la Sociedad Española de Farmacia Industrial y Galéncia (SEFIG): "Biodisponibility and Bioequivalencia", Valencia, Spain; February 7, 2001.
59. Speaker at Symposium titled "Can a Once-Daily Methylphenidate Patch Help Children with ADHD?" at the 48th Annual American Academy of Child & Adolescent Psychiatry: "Methylphenidate Pharmacokinetics After Dosing With A Once-Daily Transdermal System", Honolulu, Hawaii; October 27, 2001.
60. Poster presentation titled at the 48th Annual American Academy of Child & Adolescent Psychiatry: "Methylphenidate Bioavailability from an Extended-Release Capsule Administered Sprinkled or Intact " Honolulu, Hawaii; October 25, 2001.
61. Poster presentation titled at the 48th Annual American Academy of Child & Adolescent Psychiatry: "Methylphenidate Bioavailability Assessment From Two Modified Release Formulations", Honolulu, Hawaii; October 25, 2001.

62. Speaker at XXVII Congreso Centroamericano y del Caribe de Ciencias Farmacéuticas: "Conceptos de Bioequivalencia e Interpretaciones Equivocadas," Antigua, Guatemala; November 30, 2001.
63. Invited lecturer at 2-day seminar for Instituto Nacional de Higiene "Uso de la Farmacocinética en la Evaluación de Medicamentos," Caracas, Venezuela; January 22-23, 2002.
64. Speaker at ExpoFarma Congress & Exhibition: "Evolución de los Medicamentos Genéricos en las E.U.A.," México, D.F., March 14, 2002.
65. Workshop Speaker at Asociación Farmacéutica Mexicana's (AFM) Seminario Internacional de Medicamentos Genéricos Intercambiables: "Sistema de Clasificación Biofarmacéutica", México, D.F.; April 4, 2002.
66. Workshop Speaker at AFM's Seminario Internacional de Medicamentos Genéricos Intercambiables: "Aspectos Científicos de los Estudios de Bioequivalencia y Requisitos del FDA", México, D.F.; April 5, 2002.

Volunteer Service:

American Association of Pharmaceutical Scientists (AAPS)

1. Chairman of PPDM Nominating Committee for 1987, 1988.
2. Chairman of Symposium for PDD Section at AAPS National Meeting, 1988.
3. PPDM Program Committee Member for Atlanta Meeting, 1988.
4. Candidate for Vice-Chair of PPDM , 1989.
5. Chairman of Symposium for PPDM Section at AAPS National Meeting, 1989.
6. Co-Chairman of PPDM Program Committee for Las Vegas Meeting, 1990.
7. Member of AAPS Task Force on Generic Drugs, 1990; AAPS spokesman at Blue Ribbon Committee on Generic Medicines Public Hearing, June 20, 1990 in Washington, DC.
8. Member of the AAPS Future Events Committee, 1990.
9. Vice-Chairman of Dermatopharmaceutics Focus Group, 1991.
10. Chairman of PPDM Publicity Committee, 1991.
11. Fund Raiser and Organizing Chairman for PPDM Open Forum I, 1991.
12. Chairman of Dermatopharmaceutics Focus Group, 1992.

13. Chairman Open Forum II Planning Committee, 1992.
14. Chairman of PPDM Publicity Committee, 1992, 1993.
15. Chairman of AAPS Publicity Committee, 1992, 1993.
16. Member of FDA/AAPS Workshop on Scale-Up of Oral Controlled-Release Dosage Forms, 1992.
17. Moderator for the AAPS/FDA Workshop on Evaluation of Orally Administered Highly Variable Drugs and Drug Formulations, March 6-8, 1995.
18. Planning Committee Member for FDA/AAPS Workshop on Scale-Up on Heterogeneous Formulations, 1992-93.
19. Member of Annual Program Committee, 1993.
20. Vice-Chair of PPDM, 1993.
22. Chair-Elect of PPDM for 1994.
22. Chair of PPDM for 1995.
23. Moderator for the AAPS/FDA Workshop on Evaluation of Orally Administered Highly Variable Drugs and Drug Formulations, March 6-8, 1995.
24. Co-Chair of Planning Committee for AAPS/FDA/USP Workshop IV: Scale-Up of Adhesive Transdermal Drug Delivery Systems, 1995-96.
25. Co-Chair of AAPS Pharmaceutical Congress of the Americas to be held March 23-29, 2001.

Controlled Release Society (CRS)

1. Member of CRS Programming Committee, 1992-93.
2. Chair of Workshop on Scale-up & Manufacturing Site Change at the 21st International Symposium on Controlled Release of Bioactive Materials: Nice, France, June 24-25, 1994.
3. Invited by the Argentina CRS Chapter to be sole presenter at a One-Day Workshop for the Regional CRS Meeting. Topic: "The Role of Pharmacokinetics In The Evaluation of Oral Extended-Release Formulations" to be presented in Buenos Aires, Argentina, August 9, 1999.

4. Co-Chair of Workshop on *In Vitro/in Vivo* Correlations Applicable to Extended-Release Formulations, Paris, France, July 8-9, 2000.
5. Co-Chair of "Emerging Fields of Oral Drug Delivery", The Eurand Award 2000, at the CRS Meeting, Paris, France, July 12, 2000.

European Journal of Pharmaceutics and Biopharmaceutics

1. International Editorial Board Member, 1992-present.
2. Author of nine "FDA Update" articles in EJPB in 1993 and 1994.
3. Editor (with Gordon Flynn, Ph.D. as Co-Editor) of the EJPB special issue on Transdermal Pharmacokinetics published in June, 1995, vol. 41, 3.

Publications:

1. M.A. González, J. Nematollahi, W.I. Guess, and J. Autian: Diffusion, Permeation, and Solubility of Selected Agents In and Through Polyethylene, J. Pharm. Sci., **56**, 1288-1293, 1976.
2. M.A. González, T.N. Tozer, and D.T.T. Chang: Nonlinear Tissue Disposition: Salicylic Acid in Rat Brain, J. Pharm. Sci., **64**, 99-103, 1975.
3. L. Kisareck, P. Winston, and M.A. González: The Biological Half-Lives of Molybdenum as Based upon Biphasic Urinary Excretion in the Rat, Interface, **5**, 45-46, 1976.
4. R.A. Landay and M.A. González: Effect of Phenobarbital on Theophylline Disposition, J. Allergy and Clinical Immunology, **62**, 27-29, 1978.
5. G. Larsen, R. Barron, R. Landay, and M.A. González: The Effect of Intravenous Aminophylline on Pulmonary Function in Cystic Fibrosis, Amer. Review Resp. Dis., **117**, 1978.
6. P. Goldberg, M.A. González, L. Gogenola, and F. Leffert: Comparison of Repeated Bolus Injection of Theophylline to Continuous Infusion in the Treatment of Asthma in Children, Ibid, **117**, 1978.
7. R. Gurny, M.A. González, D. Kildsig, and G.S. Banker: The Determination of Entrapment Efficiency for a Molecular Dispersion System, Drug Development and Industrial Pharmacy, **5**, 437-445, 1979.
8. J.W. Georgitis, H. Eigen, M. Glick, R. Warner and M.A. González: Theophylline Absorption in Cystic Fibrosis, Amer. Rev. Resp. Dis., **119**, 276, 1979.

9. G.L. Larsen, R.J. Barron, R.A. Landay, and M.A. González: Intravenous Aminophylline in Patients with Cystic Fibrosis: Pharmacokinetics and Effect on Pulmonary Function Am. J. Dis. Child., 134, 1143-1148, 1980.
10. P.B. Goldberg, M.A. González, L. Gogenola, G. Zerbe, and F. Leffert: IV Aminophylline Therapy for Asthma: A Comparison of Two Methods of Administration in Children., Amer. J. Dis. Child., 134, 596-599, 1980.
11. J.L. Yaeger, R. Gurny, M.A. González, R. Sjoqvist, and G.S. Banker: Bioavailability Assessment of Polymer Interacted Dextropropoxyphene from Rectal Dosage Forms, Pharmazeutische Industrie, 42, 1141-1143, 1980.
12. C. Williams, C.S. Huang, R. Erb, and M.A. González: High-Performance Liquid Chromatographic Assay for Plasma Dipyridamole Monitoring, J. Chrom. Biomed. Applications, 225, 225-230, 1981.
13. F.C. Robinson, R.N. Warner, and M.A. González: Predicting Individual Phenytoin Serum Levels of Patients Seen in a Private Office Practice, Neurology, 31, 761-763, 1981.
14. J.W. Georgitis, H. Eigen, M. Glick, R. Warner, and M.A. González: Oral Theophylline Disposition in Cystic Fibrosis, Annals of Allergy, 48, 175-177, 1982.
15. C. Williams, P.R. Mayer, and M.A. González: Comparative Bioavailability of Dipyridamole from Two Tablet Formulations, Current Therapeutic Research, 32, 236-242, 1982.
16. N. Patel, G.S. Banker, D. Kildsig, and M.A. González: Paired-Ion High-Performance Liquid Chromatographic Assay for Sulfinpyrazone in Plasma, J. Pharm. Sci., 71, 1413-1315, 1982.
17. M.A. González and A.L. Golub: Theo-Dur Sprinkle: Controlled-Release Delivery Systems for Theophylline, Drug Development and Industrial Pharmacy, 9, 1279-1396, 1983.
18. A.L. Golub and M.A. González: The Relevance of Projected Theophylline Concentration Curves, In Sustained Release Theophylline in the Treatment of C.R.A.O., J.H.G. Jonkman, J.W. Jenne, and F.E.R. Simons (Eds.), Excerpta Medica, Princeton, 1984.
19. A.B. Straughn, M. Meyer, A. Golub, and M.A. González: A Chronopharmacokinetic Model for Controlled-Release Formulations, In Annual Review of Chronopharmacology, A. Reinberg, M. Smolensky, and G. Labrecque (Eds.), Pergamon Press, New York, 1984.
20. A.B. Straughn, M.C. Meyer, A.L. Golub, and M.A. González: Administration of Theo-Dur Once Daily VS Twice Daily, In Sustained Release Theophylline and Nocturnal Asthma, A.F. Isles and PI Von Wichert (Eds.), Excerpta Medica, Princeton, 1985.
21. P.K. Noonan, M.A. González, D. Ruggirello, J. Tomlinson, E. Babcock-Atkinson, M. Ray, A. Golub, and A. Cohen: Relative Bioavailability of a New Transdermal Nitroglycerin Delivery System, J. Pharm. Sci., 75, 688-691, 1986.

22. A. Golub, R.W. Frost, C.J. Betlach, and M.A. González: Physiologic Considerations in Drug Absorption from the Gastrointestinal Tract, J. Allergy and Clinical Immunology, 78, 689-694, 1986.
23. A. McLean, E. Babcock-Atkinson, K. Rein, D. Ruggirello, M.A. González, and P. Noonan: High Performance Liquid Chromatographic (HPLC) Assay Using Fluorescence Detection for the Simultaneous Determination of Gallopamil and Norgallopamil in Human Plasma, Pharmaceutical Research, Vol. 4, No. 4, 1987.
24. A. McLean, D. Ruggirello, E. Babcock-Atkinson, K. Rein, M.A. González, and P.K. Noonan: Liquid Chromatographic assay Using Fluorescence Detection for the Simultaneous Quantification of Gallopamil and Norgallopamil in Human Plasma, Pharmaceutical Research, 4, 327-331, 1987.
25. T.L. Ling, J.P. Yee, A. Cohen C. Hsiao, M.A. González, D.C. Garg, and D.J. Weidler: A Multiple-Dose Pharmacokinetic Comparison of Naproxen as a Once-Daily, Controlled-Release Tablet and a Twice-Daily Conventional Tablet, J. Clin. Pharmacology, 27, 325-329. 1987.
26. C.J. Betlach, J.D. Arnold, R.W. Frost, P.T. Leese, and M.A. González: Bioavailability and Pharmacokinetics of a New Sustained-Release Potassium Chloride Tablet. Pharmaceutical Research, Vol. 4, No. 5, 409-411, 1987.
27. A.B. Straughn, C.J. Betlach, M.C. Meyer, E.J. Jarvi, and M.A. González: Effect of Ranitidine-Induced Achlorhydria on the Absorption of Theophylline from a CR Formulation, Pharm. Res., 4, S80, 1987.
28. C.J. Betlach, A.B. Straughn, E.J. Jarvi, C.F. Ryan, J.C. Kisicki and M.A. González: Chronopharmacokinetics of Theophylline from a Once-A-Day Tablet Dosed in the Morning and at Night in Annual Review of Chronopharmacology, A. Reinberg, M. Smolensky, G. Labrecque (Eds.), Pergamon Press, Oxford, England, 1988.
29. D.A. Ruggirello, P.K. Noonan, M.A. González, P. Ho, and J.G. Wagner: Gas Chromatographic Determination of Gallopamil and Norgallopamil in Human Plasma, J. Chrom. Biomed. Application, 487, 73-80, 1989.
30. P.K. Noonan and M.A. González: Pharmacokinetics and the Variability of Percutaneous Absorption, J. Toxicol. and Cutaneous and Ocular Toxicol., Vol. 8, No. 4, 511-516, 1989.
31. A.M. McLean, D.A. Ruggirello, C. Banfield, M.A. González, and M. Bialer: Application of a Variance Stabilizing Transformation Approach to Linear Regression of Calibration Lines, J. Pharm. Sci., Vol. 79, No. 11, 1005-1008, 1990.
32. A.M. McLean, E.A. Cefali, J.S. Roden, and M.A. González: Stability of Diltiazem in Different Biological Fluids, Biopharm. Drug Disposition, 12, 327-334, 1991.

33. C.J. Betlach, A.B. Straughn, M.C. Meyer, M. Bialer, V.I. Vashi, P. Lieberman, and M.A. González: The Effect of Raising Gastric pH with Ranitidine on the Absorption and Elimination of Theophylline from a Sustained-Release Theophylline Tablet, Pharmaceutical Research, Vol. 8, No. 12, 1516-1519, 1991.
34. P.K. Noonan, D.A. Ruggirello, J.J. Tomlinson, and M.A. González: Pharmacokinetic Considerations in Transdermal Nitroglycerin Delivery, In Transdermal Drug Delivery '86, H. Jaeger, H. Mosberg, H. Plettenberg, and I. Klingmann (Eds.), IDA Verlag, Neu-Ulm, W. Germany, 1991.
35. R.C. Jewell, C. Banfield, P.K. Noonan, D. Ruggirello, Y. Huang, and M.A. González: Dose-Proportionality of Transdermal Nitroglycerin, Pharm. Research, Vol. 9, No. 10, 1284-1289, 1992.
36. M.A. González, Trends in Transdermal Drug Delivery, Chapter 8 in Topics in Pharmaceutical Sciences, 1991, D.J.A. Crommelin and K.K. Midha (Eds.), Medpharm Scientific Publishers, Stuttgart, 1992.
37. Skelly, van Buskirk, Savello, Amidon, Arbit, Dighe, Fawzi, González, Malick, Malinowski, Nedich, Pearce, Peck, Schwartz, Shah, Shangraw, and Truelove: Scale-up of Immediate Release Oral Solid Dosage Forms: Workshop Report, Eur. J. Pharm. Biopharm., 39, (1), 40-43, 1993.
38. E.A. Cefali, C.R. Banfield, M.A. González, and J.G. Wagner: In Vivo Determination of Zero-order Absorption from a Transdermal Glycerol Trinitrate System, Eur. J. Pharm. Biopharm., 39, (4), 140-143, 1993.
39. Skelly, van Buskirk, Arbit, Amidon, Augsburger, Barr, Berge, Clevenger, Dighe, Fox, González, Gray, Hoiberg, Jerussi, Leeson, Lesko, Malinowski, Nixon, Pearce, Peck, Porter, Robinson, Savello, P. Schwartz, J.B. Schwartz, Shah, Theeuwes, and Wheatley: Workshop II Report: Scale-up of Oral Extended Release Dosage Forms, Eur. J. Pharm. Biopharm., 39, (4), 162-167, 1993.
40. J.P. Skelly and M.A. González: FDA Update: Dissolution Testing: Simple Tool-Important Contribution, Eur. J. Pharm. Biopharm., 39 (5), 173-228, 1993.
41. C.J. Betlach, M.A. González, B.C. McKiernan, C.Neff-Davis, and N. Bodor: Oral Pharmacokinetics of Carbamazepine in Dogs from Commercial Tablets and a Cyclodextrin Complex, J. Pharm. Sci., Vol. 82, No. 10, 1058-1060, 1993.
42. M.A. González: Farmacocinetica e Farmacodinamica Della Nitroglicerina Transdermica, Argomenti di Cardiologia, Anno 5, Vol. 5, Suppl. 1, 1994.
43. M.A. González, J. Kisicki, and A.B. Straughn: Pharmacokinetic Comparison of a Once-Daily and Twice-Daily Theophylline Delivery System, Clin. Ther., Vol. 16, No. 4, 686-692, 1994.

44. M.A. González and A.B. Straughn: Effect of Meals and Dosage-Form Modification on Theophylline Bioavailability from a 24-Hour Extended-Release Delivery System, Clin. Ther., Vol. 16, No. 5, 804-814, 1994.
45. Skelly, van Buskirk, Savello, Amidon, Arbit, Dighe, Fawzi, González, Malick, Malinowski, Nedich, Pearce, Peck, Schwartz, Shah, Shangraw, and Truelove: Scale-up of Immediate Release Oral Solid Dosage Forms: AAPS/FDA Workshop Committee, Pharm. Tech., 68-74, April, 1995.
46. Theme Issue on Transdermal Pharmacokinetics, M. A. González & G.L. Flynn (Eds.), Eur. J. Pharm. Biopharm., 41 (3), 1995.
47. Shah, Yacobi, Barr, Benet, Breimer, Dobrinska, Endrenyi, Fairweather, Gillespie, González, Hooper, Jackson, Lesko, Midha, Noonan, Patnaik, and Williams: Evaluation of Orally Administered Highly Variable Drugs and Drug Formulations: AAPS/FDA Workshop Report, Pharm. Research, Vol. 13, No. 11, 1590-1594, 1996.
48. Van Buskirk, González, Shah, Barnhardt, Barrett, et. al.: Scale-up of Adhesive Transdermal Drug Delivery Systems: AAPS/FDA Workshop Report, Pharm. Research, Vol. 14, No. 7, 848-852, 1997.
49. M.A. González and K. S. Estes: Pharmacokinetic Overview of Oral Second-Generation H₁ Antihistamines, International J. Clin. Pharmacol. Therap., Vol. 36, No. 5, 292-300, 1998.
50. M.A. González, et. al: Methylphenidate Bioavailability from Two Extended-Release Formulations, International J. Clin. Pharmacol. Therap., Vol 40, No. 4, 175-84, 2002.
51. G. Hochhaus, M.A. González, R.J. Dockhorn, J. Shilstone, J. Karafilidis: A New Solution-Based Intranasal Triamcinolone Acetonide Formulation in Patients with Perennial Allergic Rhinitis: How Does the Pharmacokinetic/Pharmacodynamic Profile for Cortisol Suppression Compare with an Aqueous Suspension-Based Formulation?, J. Clin. Pharmacol., 42, 662-669, 2002.
52. M.A. González: Estudios de Bioequivalencia Y México, InformaCéutico, Vol 3, No. 3, 20, 2002.